Evolocumab has no negative impact on cognitive function among paediatric patients with FH

Key findings from the study are:

• ANCOVA results indicated no decrease in performance across visits during 80 weeks of evolocumab treatment for a computerized battery of cognitive tests, including Groton Maze Learning (executive function), One Card Learning accuracy (visual learning), Identification speed (visual attention), or Detection speed (psychomotor function).
• Performance on all tasks was similar for those who received placebo or evolocumab in the RCT.
• For all tests, the least square mean differences between patients taking placebo vs evolocumab were trivial (parent study).

In this study, they tested whether treating children with evolocumab for 80 weeks affected their mental ability to perform several tasks. A battery of tests showed no decrease in performance across visits during 80 weeks of evolocumab treatment.

Reference:

Raul D Santos et al. Evolocumab in paediatric heterozygous familial hypercholesterolaemia: cognitive function during 80 weeks of open-label extension treatment, European Journal of Preventive Cardiology, 2023; zwad332, https://doi.org/10.1093/eurjpc/zwad332